Asgard Therapeutics raises 30 MEUR

(Lund, direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies): Has raised 30 MEUR in a funding round from Novo Nordisk, JJDC, RV Invest and Industrifonden with member Peter Wolpert. “Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient’s body, comments Cristiana Pires, CEO of Asgard Therapeutics.